Abzena is the leading end-to-end bioconjugate and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.

We Provide Best-in-Class & End-to-End Support For:
• Antibodies (mAbs)
• FAbs
• Antibody-drug Conjugates (ADCs)
• Bispecifics
• Radioconjugates
• Fusion Proteins
• Growth Factors
• Recombinant & Conjugate Vaccines
• Cytokines
• Biosimilars
• Antibody–oligonucleotide conjugates (AOCs)
• Nanoparticles

With Comprehensive Capabilities Ranging From:
• Early-Stage Research & Discovery, Design and Lead Selection
• Robust Analytics, Bioassays and Immunogenicity Assays
• Bioconjugation & Chemistry
• Antibody Engineering and Developability
• Mammalian Cell Line Development
• Linker Payload Design and Synthesis
• Analytical Method & Formulation Development
• Process Development and cGMP Manufacturing up to 2000L
• Master Cell Banking
• Technology Transfer & Scale-Up
• Regulatory Support

Our extensive toolkit of services is designed to ensure our customers achieve their Target Product Profile (TPP). With early-stage research, process development and cGMP manufacturing capabilities all under a single organization, we can leverage our vast capabilities and knowledge of the product, along with the requisite In Vitro and In Vivo criteria to ensure that the desired TPP can be accomplished from the project outset.